Category: PRN Asia

Biosyngen’s Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

SINGAPORE, June 6, 2023 /PRNewswire/ — Jun. 1st, 2023, Biosyngen Pte. Ltd. (hereinafter as “Biosyngen”) announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) has granted to its application, for immune cell therapy BRG01for the treatment of nasopharyngeal cancer, the status of Orphan Drug Designation (ODD). The FDA Orphan […]

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449’s Potential as a New Treatment for Drug-Resistant NSCLC

SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has released updated data of APG-2449, a novel FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI) developed by Ascentage […]

CGTN: Why does China stick to the path of common prosperity?

BEIJING, June 6, 2023 /PRNewswire/ — Liu Jinliang, a second-generation beekeeper in Miyun District, the northeastern suburb of Beijing, practices multi-box beekeeping. He is China’s first beekeeper to successfully utilize the technique, introduced by the district government in 2016.   It took the young bee farmer five years to fully implement the new technique, and […]

VISION LIFE Accelerates Global Expansion, Announces Major Development Plan at Summer Conference in Tokyo

CHICAGO, June 6, 2023 /PRNewswire/ — VISION LIFE, an international group with a core business of global advertising distribution, is currently rapidly expanding its market and committed to building the world’s largest advertising community. With over 200,000 members and agents in markets such as Japan, South Korea, Taiwan, mainland China, the Philippines, Malaysia, and Singapore, […]

YOOBIC Opens Bangkok Office: Doubles Down on Asia Pacific

BANGKOK, June 6, 2023 /PRNewswire/ — YOOBIC, the all-in-one frontline employee experience platform, today announced the opening of its APAC headquarters in Bangkok, Thailand, to support the company’s rapid expansion in the region. Retail sales in Southeast Asia, Australia, and New Zealand are anticipated to hit $1.77 trillion by 2025, positioning the region as the […]

Roborock Unveils the Home Cleaning Center: Pioneering a New Era of Immaculate Homes and Enhanced Well-being

BEIJING, June 6, 2023 /PRNewswire/ — On June 1st, Roborock (688169.SH) officially announced Mr.Xiao Zhan as Roborock Global Brand Ambassador and unveiled the highly anticipated Roborock Home Cleaning Center. The state-of-the-art center seamlessly integrates Roborock’s three flagship products—sweeping robots, floor scrubbers and washer-dryer combos—into a comprehensive home cleaning solution. With the innovative collection of products, users […]

Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting

As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors (other than breast cancer and gastric/gastroesophageal junction cancer) were enrolled, 92.3% of whom had received ≥2L prior systemic therapy. The objective response rate (ORR) was 53.8% with 6.8 months median duration of response (mDOR), 5.6 months median progression survival (mPFS) and […]

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting

SUZHOU, China, June 6, 2023 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, has presented updated data of Cohort C from a phase I/IIa, multi-center study of Osemitamab (TST001) in combination with Capecitabine and Oxaliplatin (CAPOX) as a […]

Back To Top